

Certification of Mailing or Facsimile Transmission

I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being submitted as indicated below:

[x] mailed or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

[] facsimile transmitted to the U.S. Patent and Trademark Office via fax number 571-273-8300

Naishadh N. Desai 50,630

Registration No (if applicable)

Signature

December 27, 2005

Date

Trut

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/649,852

Applicant(s)

Robert Joseph Isfort

Filed

08/27/2003

Title

Methods For Identifying Compounds For Regulating

Muscle Mass or Function Using Corticotropin

Releasing Factor Receptors

TC/A.U.

Examiner -

Shulamith H. Shafer

Conf. No.

7224

Docket No.

8448R

1647

Customer No.

27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

01/03/2006 HDEMESS1 00000082 162480 10649852

Commissioner for Patents

01 FC:1806

180.00 DA

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [x] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

•	1.98(a)(2), copies of only foreign patent documents
and non-patent literature are enclosed	
prior application Case No, Upriority is claimed to said application previously submitted references are	OR e previously cited by or submitted to the USPTO in U.S. Patent Application Serial No, filed on under 35 U.S.C. §120. Accordingly, copies of not provided with this Statement, pursuant to 37 equested that all the cited documents be carefully e of record in this case. OR
Copies of the foreign and non-patent all other documents listed on this P parent application U.S. Patent Appli Priority is claimed to said application previously submitted references are	cited in this Information Disclosure Statement. documents, if applicable, are enclosed. Copies of TO-SB08 form were submitted and considered in cation Serial No, filed on under 35 U.S.C. §120. Accordingly, copies of not provided with this Statement, pursuant to 37 equested that all the cited documents be carefully
[] Pursuant to 37 C.F.R. §1.98(c) cited reference that is not in the Engli), a concise explanation of the relevance of each ish language is provided.
[] It is respectfully requested that pending applications listed on the atta	the Examiner consider and make of record the co- achied page.
[] The International Search Report SB08 and a copy is attached.	t from the PCT/EPO is noted on page of the PTO-
[] Additional information is attach	ned.
	Respectfully submitted,
	THE PROCTER & GAMBLE COMPANY
	Sin
	Signature
Data: December 27, 2005	Naishadh N. Desai
Date: December 27, 2005 Customer No. 27752	Registration No. 50,630 (513) 622-0087

(IDS.doc) (Last Revised 10/25/2005)

:	FEE TRANSMITTAL	Complete if Known			
	for FY 2005	Application Number	10/649,852		
	Platent fees are subject to annual revision.	Confirmation Number	7224		
	Effective December 8, 2004	Filing Date	08/27/2003		
	DEC 3 0 7 nns	First Named Inventor	Robert Joseph Isfort		
	DEC	Examiner Name	Shulamith H. Shafer		
1		Art Unit	1647		
	TOTAL AMOUNT OF PAYMENT (\$)180	Attorney Docket No.	8448R		

METHOD OF PAYMENT	FEE CALCULATION (continued)	
1. [X] The Director is hereby authorized to charge indicated fees submitted on this form, credit any over payments, and	5. <u>ADDITIONAL FEES</u> Fee Description	Fee Paid
charge any additional fee(s) during the pendency of this	Extension for reply within 1 st month (\$120)	
application to:	Extension for reply within 2 nd month (\$450)	Ö
Deposit Account Number: 16-2480	Extension for reply within 3 rd month (\$1,020)	
Deposit Account Name: The Procter & Gamble Company	Extension for reply within 4 th month (\$1,590)	~~
FEE CALCULATION	Extension for reply within 5 th month (\$2,160)	
2. BASIC FILING FEE - Large Entity	,	
FILING SEARCH EXAMINATION FEE FEE FEE	Information Disclosure Statement fee (\$180)	[x]
Application	37 CFR 1.16(e) Late Oath/Declaration	
Type Fee Paid	(nonprovisional) (\$130)	[]
Utility (\$300) (\$500) (\$200)	37 CFR 1.17 (q) Missing Parts (provisional) (\$50)	Ö
(Total = \$1000) []		
Design (\$200) (\$100) (\$130)	Non-English specification (\$130)	
(Total = \$430) []		
Reissue (\$300) (\$500) (\$600)	Notice of Appeal (\$500)	[]
(Total = \$1400) []		
Provisional filing fee (Total = \$200) []	Filing a brief in support of an appeal (\$500)	[]
3. APPLICATION SIZE FEE:	Request for oral hearing (\$1,000)	· []
Sheets of Spec and Drawings []	(ψ1,000)	, fl
(\$250 for each 50 sheets in excess of 100, except for	Acceptance of unintentionally delayed claim for priority	
sequence and program listings)	under 35 U.S.C. 119, 120, 121, or 365 (a) or (c) (\$1,370)	П
SUBTOTAL (2)+(3) (\$)[]	Other:	Ö
4. EXTRA CLAIM FEES FOR UTILITY AND REISSUE:	•	
Extra Fee from Fee		
<u>Claims</u> <u>Below</u> <u>Paid</u>		
Total Claims [] $-20** = [] x$ [] = []		
Independent Claims [] - $3** = [] \times [] = []$		
Multiple Dependent claims: [] = []		
** or number previously paid, if greater; For Reissues, see below		
Fee Description		
Claims in excess of 20 (\$50 per claim)		
Independent claims in excess of 3 (\$200 per claim)		
Multiple dependent claim, if not paid (\$360)		
**Reissue: each independent claim over 3 and more than in the original patent (\$200 per claim)		
**Reissue claims: each claim over 20 and more than original patent (\$50 per claim)		
SUBTOTAL (4) (\$)[]	SUBTOTAL(5)	(\$) [180]

SUBMITTED BY				Com	Complete (if applicable)	
Name (Print/Type)	Naishadh N. Desai	Registration No. (Attorney/Agent)	50,630	Telephone	(513) 622-0087	
Signature				Date	December 27, 2005	

This collection of information is required by 37 CFR 1.17. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Feetrans.doc (Revised for P&G use 01/24/2005)

rectalis,doc (Nevised for Fact use 01/24/2005

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are equired to respect to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

de la concetton of information uness it	
COMPLET	TE IF KNOWN
Application Number	10/649,852
Confirmation Number	7224
Filing Date	08/27/2003
First Named Inventor	Robert Joseph Isfort
Group Art Unit	1647
Examiner Name	Shulamith H. Shafer
Attorney Docket Number	8448R

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-	WW. BB 1111	Document	Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	1	WO 97/00063 A2	01/03/1997	Vale, et al.		
	2	EP 0 860 501 A2	08/26/1998	Lovenberg, et al.		
	3	WO 96/37223 A1	11/28/1996	Grabstein, et al.		
EXAMINER				DATE CONSIDERED	1.	<u></u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/5/2004)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Order the raperwork Reduction Act of 1993, no persons are required to resp	ond to a collection of information unless if	contains a valid OMB control number	
Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
	Application Number	10/649,852	
INFORMATION DISCLOSURE	Confirmation Number	7224	
STATEMENT BY APPLICANT	Filing Date	08/27/2003	
(use as many sheets as necessary)	First Named Inventor	Robert Joseph Isfort	
	Group Art Unit	1647	
	Examiner Name	Shulamith H. Shafer	
SHEET 2 of 2	Attorney Docket Number	8448R	

NON PATENT LITERATURE DOCUMENTS

Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
4	H.A. THOMAS, ET AL., "CRF and Related Peptides as Anti-Inflammatory Agonists", <i>Annals New York Academy of Sciences</i> , 1993, Vol. 697, pp. 219-228.	
5	.R. MCCARTHY, ET AL., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents", <i>Annual Reports in Medicinal Chemistry</i> , 1999, Vol. 34, Academic Press, pp.11-20,	
R	DATE CONSIDERED	
	No.1 4 5	H.A. THOMAS, ET AL., "CRF and Related Peptides as Anti-Inflammatory Agonists", Annals New York Academy of Sciences, 1993, Vol. 697, pp. 219-228. R. MCCARTHY, ET AL., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents", Annual Reports in Medicinal Chemistry, 1999, Vol. 34, Academic Press, pp.11-20,

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 11/4/2004)

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.